Plant-Derived MoMo30 Protein for Broad-Spectrum Viral Entry Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for broad spectrum antimicrobial agents that can effectively bind and neutralize microorganisms, particularly viruses, by mimicking the properties of lectins to inhibit viral entry and stimulate host immune responses.
Innovation Solution
A plant-derived MoMo30 protein with a specific amino acid sequence, derived from the Momordica genus, is used in compositions and methods to inhibit viral infections by blocking viral entry into host cells and stimulating a neutralizing antibody response, with properties including high heat stability and mannose-sensitive binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional antimicrobial agents are used, then specific viral infections may be treated, but broad spectrum antiviral activity is not achieved
Solution Approach 1:
The patent applies universality by designing a lectin-based antiviral agent that can bind to mannose residues on multiple different viral surfaces simultaneously. The MoMo30 protein exhibits broad-spectrum antiviral activity against diverse viruses including HIV, Ebola, influenza, and coronaviruses, while maintaining reliable inhibition through its specific carbohydrate-binding capability. This multi-functional approach allows a single agent to address multiple viral threats without sacrificing effectiveness.
2Reliability
If lectin proteins are used to bind viral glycans, then viral entry is inhibited, but the complexity of identifying effective lectins increases
Solution Approach 1:
The patent applies copying by utilizing the naturally occurring MoMo30 lectin protein from plant sources that has already evolved the required binding specificity. Instead of synthesizing or screening numerous artificial lectin variants, the invention copies the effective carbohydrate-binding structure from nature. This approach simplifies the identification process while maintaining reliable viral entry inhibition through the protein's inherent mannose-binding capability.
3Reliability
If heat-sensitive lectin proteins are used, then antiviral activity is maintained, but stability and shelf life are reduced
Solution Approach 1:
The patent applies parameter changes by optimizing the lectin protein's structural properties to enhance thermal stability while preserving antiviral function. The MoMo30 protein has been characterized and formulated with specific amino acid compositions and structural features that confer heat resistance. This allows the protein to maintain its carbohydrate-binding capability and antiviral activity across a broader temperature range, improving stability and shelf life without sacrificing reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
MoMo30 protein effectively inhibits a range of viruses, including HIV and Ebola, by forming stable complexes and inducing a broadly neutralizing antibody response, reducing viral loads and increasing CD4+ lymphocyte counts in treated patients.
Implementation Method 1
Lectin proteins are sugar-binding proteins that bind specifically and reversibly to carbohydrate groups. The MoMo30 protein binds HIV gp120 in a manner that is sensitive to mannose, indicating carbohydrate-mediated binding.
Implementation Method 2
These roles are mediated by specific multivalent interactions between cell surfaces decorated by complex glycans and their cognate protein lectins. The MoMo30 protein effectively inhibits a range of viruses by forming stable complexes.
Data Source
AI summary
The present application relates to a compositions and methods comprising or expressing a hevamine A-related MoMo30 protein from Momordica balsamina. The MoMo30 protein is about 30 kDa in size, is stable after being autoclaved at 120° C. for 30 min, resists proteolytic cleavage by trypsin, exhibits mannose-sensitive binding to HIV gp120, exhibits hemagglutinin and chitinase activity, is capable of activating and stimulating T cell proliferation, is capable of preventing infection by HIV-1 or alleviating symptoms in an HIV-1 infected patients, and comprises an amino acid sequence of SEQ ID NO: 4. The MoMo30 protein and/or a nucleic acid encoding the same may be used in methods for preventing or treating microbial infections by HIV, SARS-CoV-2 and other enveloped viruses, as well as other microorganisms comprising cell surface proteins containing glycan residues, such as mannose.